Publications
263
Citations
7,428
Est. group size
~7
Recurring co-author estimate
Active years
48
Publishing since 1979
Pui-Kai Li's research focuses on developing new drug therapies for advanced prostate cancer, particularly targeting hormone signaling pathways, cancer cell metabolism, and cancer stem-like cells. The work involves preclinical studies of novel inhibitors aimed at proteins and enzymes (such as AR variants, AKR1C3, steroid sulfatase, and BET proteins) that drive tumor growth and treatment resistance. Some recent work also extends to bacterial persistence mechanisms in tuberculosis.
Publication output was modest and variable from 2017-2022, then spiked sharply in 2023 (likely reflecting a burst of supplementary data records tied to a few core studies) before settling to a more moderate but still elevated level through 2024-2026.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Abstract B024: Novel therapeutics targeting BET-mediated oncogenesis in lethal prostate cancer
Cancer Research · 2026
- Targeting NDUFS4 Disrupts Oxidative Phosphorylation and Induces Ferroptosis in Olaparib-Resistant Prostate Cancer
Molecular Cancer Therapeutics · 2026
- Steroid Sulfatase Regulates Metabolic Reprogramming in Advanced Prostate Cancer
Cancers · 2025
- The pH gradient contributes to persistence in Mycobacterium tuberculosis
Research Square · 2025
- The pH gradient contributes to persistence in <i>Mycobacterium tuberculosis</i>
bioRxiv (Cold Spring Harbor Laboratory) · 2025
- Novel dual inhibitors of AR/AR variants and AKR1C3: Preclinical activities for advanced prostate cancer therapy.
Journal of Clinical Oncology · 2024
- PD16-02 CONCURRENT TARGETING AR/AR VARIANTS AND AKR1C3 FOR ADVANCED PROSTATE CANCER THERAPY
The Journal of Urology · 2023
- Supplementary Figure from JAK-STAT Blockade Inhibits Tumor Initiation and Clonogenic Recovery of Prostate Cancer Stem-like Cells
2023
- Supplementary Table 1 from JAK-STAT Blockade Inhibits Tumor Initiation and Clonogenic Recovery of Prostate Cancer Stem-like Cells
2023
- Supplementary Table 1 from JAK-STAT Blockade Inhibits Tumor Initiation and Clonogenic Recovery of Prostate Cancer Stem-like Cells
2023
- Data from JAK-STAT Blockade Inhibits Tumor Initiation and Clonogenic Recovery of Prostate Cancer Stem-like Cells
2023
- Supplementary Table 2 from JAK-STAT Blockade Inhibits Tumor Initiation and Clonogenic Recovery of Prostate Cancer Stem-like Cells
2023
- Supplementary Table 2 from JAK-STAT Blockade Inhibits Tumor Initiation and Clonogenic Recovery of Prostate Cancer Stem-like Cells
2023
- Supplementary Figure from JAK-STAT Blockade Inhibits Tumor Initiation and Clonogenic Recovery of Prostate Cancer Stem-like Cells
2023
- Data from JAK-STAT Blockade Inhibits Tumor Initiation and Clonogenic Recovery of Prostate Cancer Stem-like Cells
2023
- Cancer Research×6
- The Journal of Urology×5
- bioRxiv (Cold Spring Harbor Laboratory)×3
- Oncotarget×2
- Cancers×2
- Lianbo Yu
Medicine · The Ohio State University
- Karuppaiyah Selvendiran
Medicine · The Ohio State University
- Anindhya Sundar Das
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Sabbir Ahmed
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Evan H. Zhang
Immunology and Microbiology · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile